| 000 | 01763 a2200613 4500 | ||
|---|---|---|---|
| 005 | 20250514234858.0 | ||
| 264 | 0 | _c20050830 | |
| 008 | 200508s 0 0 eng d | ||
| 022 | _a0300-9009 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSindic, C J M | |
| 245 | 0 | 0 |
_aLong-term follow up of glatiramer acetate compassionate use in Belgium. _h[electronic resource] |
| 260 |
_bActa neurologica Belgica _cJun 2005 |
||
| 300 |
_a81-5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aBelgium |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aGlatiramer Acetate |
| 650 | 0 | 4 | _aHealth Surveys |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 | _aLuxembourg |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy |
| 650 | 0 | 4 | _aNetherlands |
| 650 | 0 | 4 | _aPatient Compliance |
| 650 | 0 | 4 |
_aPeptides _xadministration & dosage |
| 650 | 0 | 4 | _aSecondary Prevention |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSeeldrayers, P | |
| 700 | 1 | _aVande Gaer, L | |
| 700 | 1 | _aDe Smet, E | |
| 700 | 1 | _aNagels, G | |
| 700 | 1 | _aDe Deyn, P P | |
| 700 | 1 | _aMedaer, R | |
| 700 | 1 | _aGuillaume, D | |
| 700 | 1 | _aD'Hooghe, M B | |
| 700 | 1 | _aDeville, M C | |
| 700 | 1 | _aDecoo, D | |
| 700 | 1 | _aSadzot, B | |
| 700 | 1 | _aVan Landegem, W | |
| 700 | 1 | _aStrauven, T | |
| 700 | 1 | _aPepin, J | |
| 700 | 1 | _aMerckx, H | |
| 700 | 1 | _aCaekebeke, J | |
| 700 | 1 | _avan der Tool, M A | |
| 773 | 0 |
_tActa neurologica Belgica _gvol. 105 _gno. 2 _gp. 81-5 |
|
| 999 |
_c15715293 _d15715293 |
||